Sentinel Oncology awarded Technology Strategy Board Proof of Concept grant
Sentinel Oncology is pleased to announce the recent award from the Technology Strategy Board of a proof of concept grant to study the suitability of their Chk1 drugs for the treatment of Glioblastoma.
The grant will allow Sentinel to optimise the drugs' ability to penetrate the brain and help treat a type of cancer for which there are few treatment options and very poor prognosis.
Stuart Travers, COO of Sentinel Oncology said "This award has allowed us to study a type of cancer which we would have been unable to investigate otherwise. The £100,000 grant will enable us to work with key academics in the area and ultimately will inform us if there is a likelihood that Chk1 can be used in combination with the currently used therapies to benefit patients."
